Exploring the connection: endocrine disruptors and polycystic ovarian syndrome

Authors

  • M. Shakir Hussain Department of Pharmacology, King George’s Medical University, Lucknow, Uttar Pradesh, India
  • Ajit Kumar Mishra Department of Pharmacology, King George’s Medical University, Lucknow, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20241003

Keywords:

Endocrine disrupting substance, BPA, PCOS

Abstract

Polycystic ovarian syndrome (PCOS) is heterogeneous endocrine disorder in females manifesting reproductive dysfunction and metabolic abnormalities. Endocrinopathy in the form of hyperandrogenism leading to alteration in clinical phenotype and fertility seen. Atherogenic dyslipidaemia and insulin resistance as a result of metabolic disturbance also encountered. Recent years, endocrine disrupting chemicals (EDCs) are widely studied and linked for their alleged role in the development of PCOS. EDCs like bisphenol A (BPA), Phthalate, methoxychlor and chlorpyrifos which are present in many industrial as well as daily use products poses risk of development of various diseases. This review discusses the role of EDCS specially BPA in the pathogenesis of PCOS with study of interest identified and extracted from databases like Pub Med and Google scholars using MeSH keywords. BPA has estrogenic property and binds to oestrogen receptors α and β. Stimulation of ovarian theca cells and dysregulation of steroid biosynthesis leads to androgen overproduction. It stimulates GnRH Pulse generator, decreasing the level of LH hence fertility is affected. BPA also interact with adipose tissue receptors and causes differentiation, lipid deposition and inhibition of adiponectin. Its serum and urinary levels are found to be elevated in PCOS patient. In animal studies, it is found that BPA exposure causes impaired folliculogenesis, insulin resistance and DNA methylation. EDC exposure, especially BPA which is an integral constituent of many industrial and daily use items may cause PCOS possibly by altering androgen synthesis, adipocyte stimulation and epigenetic modification.

References

Rutkowska A, Rachoń D. Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2014;30(4):260-5.

Bonefeld-Jørgensen EC, Long M, Hofmeister MV, Vinggaard AM. Endocrine-disrupting potential of Bisphenol A, Bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: New data and a brief review. Environ Health Perspect. 2007;115(1):69-76.

Priya K, Setty M, Babu UV, Pai KSR. Implications of environmental toxicants on ovarian follicles: how it can adversely affect the female fertility? Environ Sci Pollut Res. 2021;28(48):67925-39.

Yokota H, Iwano H, Endo M, Kobayashi T, Inoue H, Ikushiro SI, et al. Glucuronidation of the environmental oestrogen bisphenol A by an isoform of UDP-glucuronosyltransferase, UGT2B1, in the rat liver. Biochem J. 1999;340(2):405-9.

Cobellis L, Latini G, DeFelice C, Razzi S, Paris I, Ruggieri F, et al. High plasma concentrations of di-(2-ethylhexyl)-phthalate in women with endometriosis. Hum Reprod. 2003;18(7):1512-5.

Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod. 2002;17(11):2839-41.

Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. Human exposure to bisphenol A (BPA). Reprod Toxicol. 2007;24(2):139-77.

Wazir U, Mokbel K. Bisphenol A: A concise review of literature and a discussion of health and regulatory implications. In Vivo (Brooklyn). 2019;33(5):1421-3.

Azziz R. Reproductive endocrinology and infertility: Clinical expert series polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321-36.

Eftekhar T, Sohrabvand F, Zabandan N, Shariat M, Haghollahi F, Ghahghaei-Nezamabadi A. Sexual dysfunction in patients with polycystic ovary syndrome and its affected domains. Iran J Reprod Med. 2014;12(8):539-46.

Soiza RL, Donaldson AIC, Myint PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines. 2018;9(6):259-61.

Meier RK. Polycystic Ovary Syndrome. Nurs Clin North Am. 2018;53(3):407-20.

Macut D, Bjekić-Macut J, Rahelić D, Doknić M. Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 2017;130:163-70.

Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril. 2016;106(4):948-58.

Costa EMF, Spritzer PM, Hohl A, Bachega TASS. Effects of endocrine disruptors in the development of the female reproductive tract. Arq Bras Endocrinol Metabol. 2014;58(2):153-61.

Palioura E, Kandaraki E, Diamanti-Kandarakis E. Endocrine disruptors and polycystic ovary syndrome: A focus on Bisphenol A and its potential pathophysiological aspects. Horm Mol Biol Clin Investig. 2014;17(3):137-44.

Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev. 2015;36(6):1-150.

Hewitt SC, Korach KS. Estrogenic activity of bisphenol A and 2,2-bis(p-Hydroxyphenyl)-1,1,1-trichloroethane (HPTE) demonstrated in mouse uterine gene profiles. Environ Health Perspect. 2011;119(1):63-70.

Mukhopadhyay R, Prabhu NB, Kabekkodu SP, Rai PS. Review on bisphenol A and the risk of polycystic ovarian syndrome: an insight from endocrine and gene expression. Environ Sci Pollut Res. 2022;29(22):32631-50.

Crisp TM, Clegg ED, Cooper RL, Wood WP, Andersen DG, Baetcke KP, et al. Environmental endocrine disruption: An effects assessment and analysis. Environ Health Perspect. 1998;106(1):11-56.

Pérez-Díaz C, Miranda-García M, González-Acedo M. Exposure BA, Problem I. Non-systematic review Bisphenol A Exposure and Polycystic Ovary Syndrome: An Increasing Problem. Arch Med Uni. 2021;(13):130-5.

Takeuchi T, Tsutsumi O. Serum bisphenol A concentrations showed gender differences, possibly linked to androgen levels. Biochem Biophysical Res Communications. 2002;291(1):76-8.

Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocrine J. 2004;51(2):165-9.

Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye X, Calafat AM, et al. Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. Human Reproduct. 2012;27(12):3583-92.

Mok‐Lin E, Ehrlich S, Williams PL, Petrozza J, Wright DL, Calafat AM, et al. Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. Int J Androl. 2010;33(2):385-93.

Kandaraki E, Chatzigeorgiou A, Livadas S, Palioura E, Economou F, Koutsilieris M, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metabol. 2011;96(3):E480-4.

Tarantino G, Valentino R, Somma CD, D'Esposito V, Passaretti F, Pizza G, et al. Bisphenol A in polycystic ovary syndrome and its association with liver–spleen axis. Clin Endocrinol. 2013;78(3):447-53.

Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Rev. 2012;33(6):981-1030.

Zhou W, Fang F, Zhu W, Chen ZJ, Du Y, Zhang J. Bisphenol A and ovarian reserve among infertile women with polycystic ovarian syndrome. Int J Environ Res Publ Health. 2017;14(1):18.

Rashidi BH, Amanlou M, Lak TB, Ghazizadeh M, Haghollahi F, Bagheri M, et al. The association between bisphenol A and polycystic ovarian syndrome: a case-control study. Acta Medica Iranica. 2017;759-64.

Galloway T, Cipelli R, Guralnik J, Ferrucci L, Bandinelli S, Corsi AM, et al. Daily bisphenol A excretion and associations with sex hormone concentrations: results from the InCHIANTI adult population study. Environ Heal Perspect. 2010;118(11):1603-8.

Wang T, Li M, Chen B, Xu M, Xu Y, Huang Y, et al. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metabol. 2012;97(2):E223-7.

Nakamura T, Fukuoka K, Nakano Y, Yamasaki K, Matsushita Y, Yamashita S, et al. Genome‐wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma. Cancer Sci. 2019;110(2):828-32.

Fernández M, Bourguignon N, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ Heal Perspect. 2010;118(9):1217-22.

Adewale HB, Jefferson WN, Newbold RR, Patisaul HB. Neonatal bisphenol-a exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin-releasing hormone neurons. Biol Reproduct. 2009;81(4):690-9.

Downloads

Published

2024-04-25

How to Cite

Hussain, M. S., & Mishra, A. K. (2024). Exploring the connection: endocrine disruptors and polycystic ovarian syndrome. International Journal of Basic & Clinical Pharmacology, 13(3), 403–407. https://doi.org/10.18203/2319-2003.ijbcp20241003

Issue

Section

Review Articles